Cytokinetics, Amgen increase scope of heart failure deal

Amgen and Cytokinetics agreed to expand an existing licensing deal centered on the experimental heart failure drug omecamtiv mecarbil and related compounds to include the Japanese market. The expanded deal entitles Cytokinetics to $25 million in upfront payment and as much as $50 million in milestone fees plus sales royalties.

View Full Article in:

Los Angeles Business Journal (free registration) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA